TLR4 polymorphisms T2DM patients Nondiabetic subjects Unadjusted *P value Adjusted OR (95% CI) / §P value
Asp299Gly (A/G) n = 1672 n = 570    
A/A 1531 (91.6) 499 (87.5) 0.005 1
A/G 138 (8.2) 66 (11.6)   0.68 (0.5-0.93) / 0.015
G/G 3 (0.2) 5 (0.9)   0.20 (0.05-0.82) / 0.026
A 0.96 0.93 0.002  
G 0.04 0.07    
Dominant Model        
A/A 1531 (91.6) 499 (87.5) 0.006 1
A/G + G/G 141 (8.4) 71 (12.5)   0.68 (0.49-0.94) / 0.019
Thr399Ile (C/T) n = 1683 n = 584    
C/C 1550 (92.0) 514 (88.0) 0.004 1
C/T 131 (7.8) 65 (11.1)   0.67 (0.49 – 0.92) / 0.012
T/T 3 (0.2) 5 (0.9)   0.20 (0.05 – 0.84) / 0.027
C 0.96 0.94 0.001  
T 0.04 0.06    
Dominant Model        
C/C 1550 (92.0) 514 (88.0) 0.004 1
C/T + T/T 134 (8.0) 70 (12.0)   0.65 (0.46-0.90) / 0.009
Data are presented as number of carriers (%) or proportion. *P values were computed using χ² tests to compare T2DM patients and nondiabetic subjects. § P values adjusted for ethnicity in a logistic regression analysis.
Table 1: Genotype and allele distributions of TLR4 Asp299Gly and Thr399Ile polymorphisms in T2DM patients and nondiabetic subjects.